Iris recognition makes no difference to wavefront-guided LASIK outcomes

Article

There are no statistically significant differences in outcomes when wavefront-guided LASIK is performed with or without iris recognition (IR), according to a report published in the September 2008 issue of the Journal of Cataract and Refractive Surgery.

There are no statistically significant differences in outcomes when wavefront-guided LASIK is performed with or without iris recognition (IR), according to a report published in the September 2008 issue of the Journal of Cataract and Refractive Surgery.

Theeraptep Tantayakom and colleagues from the Shiley Eye Center, University of California San Diego, California, US conducted a retrospective analysis of 112 eyes of 64 patients who had undergone wavefront-guided LASIK using the VISX CustomVue S4 IR platform (AMO) for either myopia or myopic astigmatism. The safety, efficacy, predictability and need for enhancement at three-month follow-up were analyzed and compared between those in the IR group and those in the non-IR group.

At three-months follow-up, 93% of eyes in the non-IR group and all eyes in the IR group had the same best spectacle-corrected visual acuity (BSCVA) as preoperatively or had gained one or two lines. No eye in either group lost more than one line (p=0.12). Furthermore, 96% of eyes in the IR group and 93% of eyes in the non-IR group were within ±0.50 D of the postoperative manifest refraction spherical equivalent (p=0.24) and all eyes were within ±1 D of emmetropia. Just four eyes in the IR group and 11 in the non-IR group required enhancements during the follow-up period (p=0.1).

It was the conclusion of Dr Tantayakom and co-workers that there are no differences in measured outcomes of wavefront-guided LASIK, whether IR is used or not.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.